By Dean Seal Alzamend Neuro has gotten the go-ahead from federal regulators to launch a clinical study of its treatment for major depressive disorder. The biopharmaceutical company said.
Alzamend Neuro Shares Up After Alzheimer s Trial Data morningstar.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from morningstar.com Daily Mail and Mail on Sunday newspapers.
By Michael Dabaie Alzamend Neuro Inc. shares rose 10% to $2.79 Friday after the company said it received positive topline data from a Phase 1 clinical trial for AL001 in dementia related to. | December 17, 2021